Interleukin-22 suppresses the growth of A498 renal cell carcinoma cells via regulation of STAT1 pathway

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Zhang, Fengbo ^a   Shang, Donghao ^a   Zhang, Yuhai ^a   Tian, Ye ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RECOMBINANT CYTOKINE; RECOMBINANT HUMAN INTERLEUKIN 22; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; INTERLEUKIN 22; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; STAT1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CELL DIVISION; DOSE RESPONSE; DRUG EFFECT; NUDE MOUSE; PHYSIOLOGY; TUMOR CELL LINE;

MUS MUSCULUS;

ANIMALS; BLOTTING, WESTERN; CELL DIVISION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERLEUKINS; MICE; MICE, INBRED BALB C; MICE, NUDE; STAT1 TRANSCRIPTION FACTOR;

EID: 79956368077     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020382     Document Type: Article

References (43)

1. Decastro GJ, McKiernan JM, (2008) Epidemiology, clinical staging, and presentation of renal cell carcinoma. Urol Clin North Am 35: 581-592; vi.
2. Roos FC, Hampel C, Thuroff JW, (2009) Renal cancer surgery in the elderly. Curr Opin Urol 19: 459-464.
3. Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP, (2004) Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 101: 1545-1551.
4. Motzer RJ, Russo P, (2000) Systemic therapy for renal cell carcinoma. J Urol 163: 408-417.
5. Hartmann JT, Bokemeyer C, (1999) Chemotherapy for renal cell carcinoma. Anticancer Res 19: 1541-1543.
6. Pantuck AJ, Zisman A, Belldegrun AS, (2001) The changing natural history of renal cell carcinoma. J Urol 166: 1611-1623.
7. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, et al. (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17: 2530-2540.
8. O'Brien MF, Rea D, Rogers E, Bredin H, Butler M, et al. (2004) Interleukin-2, interferon-alpha and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: the all Ireland experience. Eur Urol 45: 613-618; discussion 619.
9. Vuky J, Motzer RJ, (2000) Cytokine therapy in renal cell cancer. Urol Oncol 5: 249-257.
10. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, et al. (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23: 133-141.
11. Dumoutier L, Louahed J, Renauld JC, (2000) Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol 164: 1814-1819.
12. Yao S, Huang D, Chen CY, Halliday L, Zeng G, et al. (2010) Differentiation, distribution and gammadelta T cell-driven regulation of IL-22-producing T cells in tuberculosis. PLoS Pathog 6: e1000789.
13. Veiga-Fernandes H, Kioussis D, Coles M, (2010) Natural killer receptors: the burden of a name. J Exp Med 207: 269-272.
14. Gurney AL, (2004) IL-22, a Th1 cytokine that targets the pancreas and select other peripheral tissues. Int Immunopharmacol 4: 669-677.
15. Chung Y, Yang X, Chang SH, Ma L, Tian Q, et al. (2006) Expression and regulation of IL-22 in the IL-17-producing CD4+ T lymphocytes. Cell Res 16: 902-907.
16. Dumoutier L, Van Roost E, Colau D, Renauld JC, (2000) Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor. Proc Natl Acad Sci U S A 97: 10144-10149.
17. Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC, et al. (2005) IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 174: 3695-3702.
18. Ikeuchi H, Kuroiwa T, Hiramatsu N, Kaneko Y, Hiromura K, et al. (2005) Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum 52: 1037-1046.
19. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, et al. (2004) IL-22 increases the innate immunity of tissues. Immunity 21: 241-254.
20. Schnyder B, Lima C, Schnyder-Candrian S, (2010) Interleukin-22 is a negative regulator of the allergic response. Cytokine 50: 220-227.
21. Arias JF, Nishihara R, Bala M, Ikuta K, (2010) High systemic levels of interleukin-10, interleukin-22 and C-reactive protein in Indian patients are associated with low in vitro replication of HIV-1 subtype C viruses. Retrovirology 7: 15.
22. Nagalakshmi ML, Rascle A, Zurawski S, Menon S, de Waal Malefyt R, (2004) Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. Int Immunopharmacol 4: 679-691.
23. Radaeva S, Sun R, Pan HN, Hong F, Gao B, (2004) Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 39: 1332-1342.
24. Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, et al. (2002) Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem 277: 33676-33682.
25. Ziesche E, Bachmann M, Kleinert H, Pfeilschifter J, Muhl H, (2007) The interleukin-22/STAT3 pathway potentiates expression of inducible nitric-oxide synthase in human colon carcinoma cells. J Biol Chem 282: 16006-16015.
26. Nagakawa H, Shimozato O, Yu L, Takiguchi Y, Tatsumi K, et al. (2004) Expression of interleukin-22 in murine carcinoma cells did not influence tumour growth in vivo but did improve survival of the inoculated hosts. Scand J Immunol 60: 449-454.
27. Weber GF, Gaertner FC, Erl W, Janssen KP, Blechert B, et al. (2006) IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase. J Immunol 177: 8266-8272.
28. Zhang W, Chen Y, Wei H, Zheng C, Sun R, et al. (2008) Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res 14: 6432-6439.
29. Hernberg M, Pyrhonen S, Muhonen T, (1999) Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. J Immunother 22: 145-154.
30. Thompson CL, Plummer SJ, Tucker TC, Casey G, Li L, (2010) Interleukin-22 genetic polymorphisms and risk of colon cancer. Cancer Causes Control 21: 1165-1170.
31. Aggarwal S, Xie MH, Maruoka M, Foster J, Gurney AL, (2001) Acinar cells of the pancreas are a target of interleukin-22. J Interferon Cytokine Res 21: 1047-1053.
32. Li J, Tomkinson KN, Tan XY, Wu P, Yan G, et al. (2004) Temporal associations between interleukin 22 and the extracellular domains of IL-22R and IL-10R2. Int Immunopharmacol 4: 693-708.
33. Kim HS, Lee MS, (2007) STAT1 as a key modulator of cell death. Cell Signal 19: 454-465.
34. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, et al. (1998) Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95: 7556-7561.
35. Lee CK, Rao DT, Gertner R, Gimeno R, Frey AB, et al. (2000) Distinct requirements for IFNs and STAT1 in NK cell function. J Immunol 165: 3571-3577.
36. Zhu ZZ, Di JZ, Gu WY, Cong WM, (2010) Association of Genetic Polymorphisms in STAT1 Gene with Increased Risk of Hepatocellular Carcinoma. Oncology 78: 382-388.
37. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, et al. (2004) Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22: 4456-4462.
38. Sebolt-Leopold JS, Herrera R, (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4: 937-947.
39. Balmanno K, Cook SJ, (2009) Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 16: 368-377.
40. Krop I, Parker MT, Bloushtain-Qimron N, Porter D, Gelman R, et al. (2005) HIN-1, an inhibitor of cell growth, invasion, and AKT activation. Cancer Res 65: 9659-9669.
41. Osaki M, Oshimura M, Ito H, (2004) PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9: 667-676.
42. Anderson GM, Nakada MT, DeWitte M, (2004) Tumor necrosis factor-α in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 4: 314-320.
43. Lécart S, Morel F, Noraz N, Pène J, Garcia M, et al. (2002) IL-22, in contrast to IL-10, does not induce Ig production, due to absence of a functional IL-22 receptor on activated human B cells. Int Immunol 14: 1351-1356.